Biopharma AIM listings on the rise as Memery Crystal Acts for Biofrontera AG

he Memery Crystal team was led by corporate partner Lesley Gregory and included corporate associate Caitlin Malloy and solicitor Vickie Miller.

Lesley Gregory commented, “The number of biopharmaceutical companies listing on AIM has doubled from last year already, with Biofrontera being the fifth in the last six months.  We are delighted to have worked with Biofrontera on its admission to AIM which should, inter alia, raise its international profile in the life sciences arena and provide access to capital should further finance be required to expand the business in the future.”

Biofrontera is a German company and is listed on the Frankfurt Stock Exchange.

Editor’s notes:

– Memery Crystal is ranked among the top tier of law firms for its AIM experience, acting for smaller to medium-sized public companies and off-shore funds, as well as for their nominated advisers and brokers. The firm has been included in “Band 1” for AIM work in the most recent edition of the Chambers UK legal directory.  In the most recent edition of the Morningstar Professional Services Rankings Guide (AIM Edition), Memery Crystal has been ranked among the top two law firms based on total number of AIM clients, as well as AIM 100 clients.

– Biofrontera is a biopharmaceutical company specialising in the development of medical cosmetics and dermatological drugs for the care and treatment of skin and inflammatory diseases. Biofrontera’s main product is Ameluz, a prescription drug approved for use in Europe. The company is looking to further develop Ameluz for use with other medical conditions and is seeking regulatory approval to sell the product in other countries, in particular the USA. The company, whose adviser and broker for the flotation is finnCap, is expected to have an approximate market capitalisation of €69.3m.